title: Early fluid resuscitation with hydroxyethyl starch 130/0.4 (6%) in severe burn injury: a randomized, controlled, double-blind clinical trial.
abstract: BACKGROUND
  There are limited data on the efficacy of early fluid resuscitation with third-generation hydroxyethyl starch (HES 130) in burn injury. Adverse effects of HES on survival and organ function have been reported.
  
  
  METHODS
  In this randomized, controlled, double-blind trial, 48 patients with severe burn injury were assigned to receive either lactated Ringer's solution plus 6% HES 130/0.4 in a ratio of 2:1 or lactated Ringer's solution with no colloid supplement for the first 72 hours. Primary outcome parameter was the group difference of administered total fluid from intensive care unit (ICU) admission up to day 3. Secondary outcomes included kidney and lung injury and failure, length of stay, and mortality.
  
  
  RESULTS
  Three-day totals of administered resuscitation fluid (medians) were 21,190 mL in the lactated Ringer's group and 19,535 mL in the HES group (HES: -1,213 mL; P = 0.39). Creatinine levels from day 1 to 3 (HES: +0.4 μmol/L; 95% confidence interval (CI) -18.7 to 19.5; P = 0.97) and urinary outputs from day 1 to 3 (HES: -58 mL; 95% CI -400 to 283; P = 0.90) were not different. Six patients in each group developed acute respiratory distress syndrome (ARDS) (risk ratio 0.96; 95% CI 0.35 to 2.64; P = 0.95). Length of ICU stay (HES vs. lactated Ringer's: 28 vs. 24 days; P = 0.80) and length of hospital stay (31 vs. 29 days; P = 0.57) were similar. Twenty-eight-day mortality was 4 patients in each group (risk ratio 0.96; 95% CI 0.27 to 4.45; P = 0.95), and in-hospital mortality was 8 in the HES group vs. 5 patients in the lactated Ringer's group (hazard ratio 1.86; 95% CI 0.56 to 6.19; P = 0.31).
  
  
  CONCLUSIONS
  There was no evidence that early fluid resuscitation with balanced HES 130/0.4 (6%) in addition to lactated Ringer's solution would lead to a volume-sparing effect in severe burn injury. Together with the findings that early renal function, incidence of ARDS, length of stay, and mortality were not negatively influenced by HES in this setting, balanced HES 130/0.4 (6%) plus lactated Ringer's solution could not be considered superior to lactated Ringer's solution alone.
  
  
  BACKGROUND
  ClinicalTrials.gov NCT01012648.
authors.forename: Markus
authors.initials: M
authors.lastname: Béchir
authors.forename: Milo A
authors.initials: MA
authors.lastname: Puhan
authors.forename: Mario
authors.initials: M
authors.lastname: Fasshauer
authors.forename: Reto A
authors.initials: RA
authors.lastname: Schuepbach
authors.forename: Reto
authors.initials: R
authors.lastname: Stocker
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Neff
mesh_terms: D002056:Burns / Q000150:complications / Q000401:mortality / Q000628:therapy*; D003404:Creatinine / Q000652:urine; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005440:Fluid Therapy; D017052:Hospital Mortality; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D007362:Intensive Care Units; D007552:Isotonic Solutions / Q000627:therapeutic use*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012128:Respiratory Distress Syndrome / Q000209:etiology; D000077325:Ringer's Lactate
chemical_list: C485123:HES 130-0.4; D006895:Hydroxyethyl Starch Derivatives; D007552:Isotonic Solutions; D000077325:Ringer's Lactate; D003404:Creatinine